I. BUSINESS AND PRODUCTION PERFORMANCES IN OCTOBER 2020
(Unit Measurement: billion dongs)
|Criteria||October 2020||YTD October 31st, 2020||% Plan 2020||YTD October 31st, 2019||Growth rate|
|Total net revenue and other income||119.7||1,013.1||57.9%||1,018.8||(0.6%)|
|Profit before tax||21.5||188.8||72.6%||156||21%|
Total net revenue and other income of Imexpharm in October slightly increased by 4% compared to last year. However, total net revenue and other income accumulated until end of October dropped by 0.6% year over year. Total net revenue was nearly kept unchanged in comparison with the figure for the previous year. Imexpharm sales are being recovered after declining in quarter 3 induced by the pandemic. The Company expects revenue in the last 2 months of the year would rise rapidly and total net revenue and income would be 1,400.2 billion dong as stated in BODs Resolution No.45 dated October 26th, 2020.
Accumulated until the end of October 2020, Imexpharm products are still playing a vital role in the revenue structure and accounted for 91.2%. In which, ETC keeps showing positive growth, as of October 31st, ETC went up about 40.3% and made up 38.3% of revenue structure. Whereas, OTC declined 10.4% and constituted 61.7% of total revenue.
Profit before tax accumulated until end of October, 2020 attained 188.8 billion dong, met 72.6% of 2020 annual plan. Profit before tax increased brightly by 21% compared to the number of 2019. Expenses are controlled tightly. In details, selling expenses dropped by 11.9% year over year while administrative expenses decreased by 5.3%. Cost of goods sold has been managed by restructuring the product portfolio and increasing the proportion of high-profit margin products. Hence, the accumulated cost of goods sold went down approximately 2.7% in comparison with the corresponding period’s result of 2019.
II. IMP STOCK IN OCTOBER 2020
In October, there were 1,715,050 shares traded. The average transaction volumes were 77,957 shares per day. There was no put-through transaction in October, all shares are dealt via order-matching. IMP stocks continue to have high liquidity after completing issuances of new shares for stock dividends and award existing shareholders. At the same time in October, Imexpharm has fulfilled the process to issue and list 2,469,300 ESOP shares. As of November 02nd, 2020, Imexpharm has listed 66,705,370 shares and there are 66,671,570 outstanding shares in the market.
III. KEY OBJECTIVES IN NOVEMBER OF 2020
In November, Imexpharm continues to strengthen customer care activities and implement many selling programs to boost OTC sales in the last 2 months of 2020. On the other hand, the Company also organizes some medical forums and seminars for experts, doctors, technicians and staff in the healthcare sectors.
Besides, the Company has been reviewing account receivables and controlling expenditures to ensure that the profit target should be reached. Imexpharm also focuses on managing inventory and observe material price fluctuations to have appropriate strategies being aligned with business and production objectives in 2021.
The epidemic is under controlled in Vietnam, but the global situation has some complicated movements; therefore, Imexpharm has been strictly applying the directions of the Government and Ministry of Health on fighting against the pandemic in parallel with maintaining business continuity.